32 Biosciences "Three Squared"’s Post

Why do surgical site infections (SSIs) still happen, despite decades of effort and huge investments in prevention? John Alverdy, MD, a world-renowned expert on SSIs, has spent his career seeking answers. In a recent JAMA Surgery article, he dives into the current standard of care and proposes new strategies to tackle drug-resistant SSIs—highlighting the often-overlooked role of the gut microbiome in their origin. At 32 Biosciences, we're taking this research further with a groundbreaking, non-antibiotic anti-infective drug developed by Dr. Alverdy. Designed to collaborate with the gut microbiome, this drug aims to reduce SSI incidence while avoiding the spread of antimicrobial resistance. A smarter, safer future for surgical outcomes could be just around the corner. #SSI #Microbiome #AntimicrobialResistance #SurgicalInnovation #HealthTech #GutHealth

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics